In this study, we investigated the feasibility of incorporating protein drugs into electrospun fibrous mats (EFMs) for wound healing using lysozyme as a model drug. Lysozyme nanoparticles (Lyso-NPs) were first obtained by electrospray. Lysozyme solutions were prepared with a binary solvent mixture of ethanol (EtOH)-water (H 2 O) at varied volume ratios. Subsequently, Lyso-NPs were suspended in poly(lactic-co-glycolic acid) (PLGA) solutions using trifluoroethanol (TFE) as a solvent. Lyso-NPs loaded EFMs were obtained by electrospinning of the aforementioned suspensions, and the bioactivity of lysozyme in the EFMs was investigated using fluorescencebased assay kit. The electrosprayed Lyso-NPs were spherical with barely altered bioactivity as compared to the untreated raw material when using EtOH-H 2 O (30:70, v/v) as the solvent. After the subsequent electrospinning process, more than 90% of the bioactivity of lysozyme was retained compared to the raw material. The cytotoxicity of the produced EFMs was evaluated by thiazolyl blue tetrazolium bromide (MTT) study and the proliferation and distribution of mouse fibroblast cells (L929) growing on EFMs were investigated using 4,6-diamidino-2-phenylindol dihydrochloride (DAPI) for nucleic acid staining. Nearly negligible cytotoxicity of all the EFMs was observed according to the MTT study. Furthermore, it was observed that the L929 cells grew well on the Lyso-EFMs, especially those with the modification of polyethylene glycol (PEG) that was added to improve the hydrophilicity of EFMs. This study demonstrated that the electrospray/electrospinning processes are suitable for loading biomacromolecules to produce functionalized wound dressings to promote wound healing.
Introduction
Wound dressings are expected to provide physical barriers to protect the wound area. Moreover, these should also mimic the extracellular matrix (ECM) providing adequate mechanical and structure support for cell attachment, proliferation and differentiation and thus, promoting the healing process of deep wounds and ulcers [1] [2] [3] [4] . In the recent years, wound dressings functionalized with biomacromolecules have been extensively investigated for wound healing. It has been reported that by formulating biomacromolecules, such as growth factors, into the dressing materials, wound healing could be promoted [5] [6] [7] . The biological signals can actively guide and direct cell functions [5, 8, 9] , however, the growth factors are usually unstable in vivo and can diffuse rapidly out from the target site due to exudates secretion around the wound area [10, 11] . Therefore, the injection of growth factors directly to the wound site is ineffective due to their short halflife. In order to reach high efficiency of biological effects of growth factors, a functionalized wound dressing with a controlled drug release profile is needed to promote wound healing.
Recently, electrospun fibrous mats (EFMs) have been employed to deliver biomacromolecules locally to the target wound area [6, [12] [13] [14] . For successful application of a drug delivery system loaded with biomacromolecules, two critical aspects need to be taken into account, i.e. the stability of the incorporated biomacromolecules and the release profile. The biomacromolecules can be protected from chemical, physical or enzymatic degradation after being incorporated into the release carriers [15] . However, the bioactivity of the biomacromolecules may be lost during the formulating and manufacturing processes [16, 17] .
Besides these procedures, the stability of biomacromolecules within the EFMs during storage and in vivo release should also be taken into consideration [18, 19] .
So far, various strategies such as physical adsorption [20] , blend electrospinning [21] , co-axial electrospinning [22] [23] [24] and covalent immobilization on the surface of EFMs [25] [26] [27] have been developed to prepare functionalized EFMs with biomacromolecules. The method using physical adsorption is the easiest way and the bioactivity of biomacromolecules can be well preserved, although the applications are limited due to uncontrolled release profiles [28] . Controlled release of biomacromolecules can be achieved by blend electrospinning or coaxial electrospinning. Normally, suspensions or emulsions are prepared prior to the blend electrospinning process, where aqueous solutions of biomacromolecules are suspended or emulsified in polymer solutions made of an organic solvent. In a co-axial electrospinning process, a solution of biomacromolecules and a solution of polymers are electrospun from different feeding channels. As frequently reported, the challenge for both blend electrospinning and co-axial electrospinning is to maintain the bioactivity of the biomacromolecules [16, 29] . A previous study showed that the bioactivity of alkaline phosphatase decreased dramatically after either blend electrospinning or co-axial electrospinning, and less than 50% of the bioactivity remained as compared to the untreated raw material [16] . Maintaining the bioactivity of biomacromolecules is also a challenge for covalent immobilization, where it might be affected by the process of covalent conjugation, and also inactivated after exposing in the harsh environment in vivo [30] .
In this study, lysozyme was used as a model protein drug because it is easy to obtain and the analytical methods to characterize its stability have been well reported in literature [31, 32] . PLGA was used as the EFMs forming material in this study because its application in the field of wound dressing has recently attracted more and more attention [33, 34] . However, its potential in the wound healing application has far been fully investigated. PEG, a hydrophilic polymer, was selected to formulate with PLGA in this study because it was reported that PEG could stabilize protein structure and protect lysozyme from denaturation while using organic solvent in the EFMs fabrication process [16] . In addition, it was reported that the release behaviors of lysozyme can be modified as improving the hydrophilicity of EFMs [23, 33] . Herein, fabrication of lysozyme loaded EFMs with a focus on investigation on the bioactivity of lysozyme after electrospray/electrospinning and the chemical stability of lysozyme during the release study were conducted in this study.
Materials and methods

Materials
PLGA (LA: GA, 50:50, molar ratio) with inherent viscosity (25°C, 0.1% chloroform [CHL] ) in the range of 0.61-0.74 dl/g was purchased from Evonik (Darmstadt, Germany). Lysozyme (from chicken egg white), molecular biology grade of trifluoroethanol (TFE), ethanol (EtOH), acetonitrile, trifluoroacetic acid (TFA), Tween-20, molecular biology grade of paraformaldehyde, 4,6-Diamidino-2-phenylindole dihydrochloride (DAPI), Triton-X100, poly(ethylene oxide) (PEG Mw 20,000), thiazolyl blue tetrazolium bromide (MTT) and phosphate buffered saline (PBS) tablets were all obtained from Sigma-Aldrich (Brøndby, Denmark). Mouse fibroblast cell (L929) was acquired from ATCC (Wesel, Germany), and the cell culture medium Dulbecco's Modified Eagle's Medium (DMEM) and penicillin-streptomycin (PS) were obtained from Sigma-Aldrich (Brøndby, Denmark). Fetal bovine serum (FBS) was acquired from Biowest (MO, USA). All materials were used as obtained.
Preparation of EFMs
The molecular weight of PLGA used in this study was measured using a size exclusion chromatography, which has been reported in a previous study, i.e. Mw 67,900 kDa [35] . The PLGA was dissolved in TFE at a concentration of 30% (w/v). The electrospinning setup included a syringe pump (Harvard Apparatus, Holliston, MA, USA) and a high-voltage supply (maximum of 20 kV, PS/FC20R06, Glassman High Voltage Inc., High Bridge, NJ, USA). The samples were collected on a rotating drum with the speed of 500 rpm/min at room temperature (RT) and ambient humidity. A 16 gauge needle (inner diameter 1.19 mm and outer diameter 1.65 mm) and 10 μL/min flow rate were used, and the distance between the nozzle tip to the grounded collector was 10 cm. The voltage was adjusted to get a stable cone-jet with a minimum change of approximately 9 kV. . Lyso-NPs were prepared by electrospray using the same setup as for preparing EFMs described in Section 2.2. A 27 gauge needle (Chip Quik Inc., Niagara Falls, NY, USA) was used. The flow rate was 3 µL/min, and the distance between the nozzle tip to grounded collector was 4 cm. The electrosprayed Lyso-NPs were collected and dried in a vacuum oven overnight. Lyso-NPs were dispersed into the PLGA polymer solutions and mixed well at varied mass ratios (i.e. 1:100, 2.5:100 or 5:100, Lyso: PLGA, w/w) before electrospinning. PEG was added together with Lyso-NPs to modify the lysozyme release behavior at varied mass ratios, i.e. 1:100, 5:100, 10:100, and 20:100 (PEG: PLGA, w/w). All the processing parameters for preparing LysoEFMs were the same as used for preparing EFMs as described in Section 2.2.
Preparation of lysozyme loaded EFMs
Biological activity of the incorporated lysozyme in EFMs
The bioactivity of Lyso-NPs prepared by electrospray was evaluated using a fluorescence-based EnzChek® Lysozyme Assay Kit (Molecular Probes, Eugene, OR, USA). Evaluation of the bioactivity of Lyso-NPs prepared from different formulations was used to find the formulation with the best biological activity, which was used for further electrospinning. In order to evaluate the bioactivity of Lyso-NPs after being electrospun, the samples were prepared under the same conditions as aforementioned in Section 2.2, except for adding PLGA in the electrospinning solutions. In this study, the collected beads (not fibers) (ES-(Lyso-NPs)) were dried in a vacuum oven and then dissolved in H 2 O to evaluate its biological activity using the Lysozyme Assay Kit. Freshly dissolved lysozyme (raw material) served as a control for 100% bioactivity.
Morphology of EFMs
The morphology of the prepared EFMs was characterized using scanning electron microscope (SEM, Hitachi High-Tech HITACHI, Tokyo, Japan). The samples were mounted on metal stubs with doublesided adhesive tape and coated under vacuum with gold in an argon atmosphere prior to observation. The specimens were then imaged at an accelerating voltage of 5 kV.
Water contact angle (WCA) of the EFMs
For evaluation of the hydrophilicity of the obtained EFMs, WCAs were measured using pendant drop analyzer (KRÜSS GmbH, Hamburg, Germany). A drop of water (20 µL) was added on the surface of the EFMs, and the measurements were acquired at 0, 30 min, and 1 h by observing the change of WCA over time. Each specimen was measured in triplicate.
Mechanical property
The mechanical properties of the resulted EFMs were carried out using dynamic mechanical analysis instrument (DMA Q800, TA instruments, New Castle, DE, USA). All the samples were cut into a specific rectangular shape, with a width fixed at 2 mm cut by the tools provided by TA instruments and the length (approximately 1 cm) of the EFMs was detected by the DMA instrument software (DMA Q800). The thickness of the mats was exactly measured by the electronic micrometer (Schut Geometrical Metrology, Netherland). The mechanical properties of the EFMs were studied at RT with a ramp displacement of 100 µm/min in a DMA strain rate mode. Each specimen was measured in triplicate.
In vitro release of lysozyme from EFMs
The Lyso-EFMs were cut into small squares (2 × 2 cm) for the in vitro release study. The release study was performed in TPBS medium (0.1 v/v % Tween-20 in 0.01 M PBS at pH 7.4) in 2.0 mL Eppendorf tube. Samples were incubated in a water bath with a shaking speed of 100 rpm either at 37°C or at RT. Initially, 1 mL of TPBS was added to immerse the fibrous mats, and subsequently, 200 µL medium was taken out at designated time intervals (0.5, 1, 2, 4, and 24 h) and 200 µL fresh TPBS was added to maintain the volume. Thereafter, on day 2, 4 and 7, and then every week until 56 days, a sample was taken out and the release medium was replaced with 1 mL fresh TPBS medium. The Eppendorf tube was sealed with parafilm to prevent the evaporation of the release medium during the release study.
The lysozyme concentration in the collected supernatant was analyzed by high performance liquid chromatography (HPLC) (1260 Infinity, Agilent Technologies, Santa Clara, CA, USA) using a reversed phase C18 column (300A, Phenomenex Aps, Vaerløse, Denmark) at 280 nm. The mobile phases consisted of phase A: acetonitrile/0.1% (v/ v) TFA and phase B: H 2 O/0.1% (v/v) TFA. The gradient elution started from 32% (v/v) of phase A to 60% (v/v) of phase A over 10 min and return to the starting phase ratio within further 5 min at a flow rate of 1 mL/min. The release study was performed in triplicate, and the results were presented as cumulative release as a function of time.
Chemical analysis of remained lysozyme in EFMs after release study
At the end of release study, lysozyme residue inside EFMs was characterized using a previously reported method [36] . Briefly, LysoEFMs was dissolved in TFE and centrifuged. Polymer solution was removed and the precipitated protein pellet was washed with TFE for 2 times. The protein pallet was reconstituted in 1 mL TPBS at 37°C for 1 h to determine the soluble residue in EFMs. Any remaining precipitate was reconstituted in 1 mL denaturing solution (TPBS/6M urea/ 1 mM EDTA) and incubated at 37°C for 30 min to determine the content of any physical aggregate. If any insoluble precipitate collected after previous treatment, it will be incubated with reducing solution (TPBS/ 6M urea/1 mM EDTA + 10 mM DL-dithiothereitol) to determine any disulfide-bonded aggregate.
Cytotoxicity of the EFMs
For investigating the cytotoxicity of the fabricated EFMs, the cell viability was measured using a MTT assay. Firstly, L929 cells were seeded in 96-well plates at 37°C and 5% CO 2 overnight at a density of 1 × 10 4 cells per well. EFMs were sterilized overnight using UV light followed by incubation with the pre-seeded cells. After incubation for 48 h, the EFMs were removed from the wells, and 10 µL MTT solution (5 mg/mL) was added to each well and incubated for 4 h at 37°C and 5% CO 2 . After 4 h, the supernatant was discarded, and 150 μL DMSO was added to terminate the reaction. For investigating the cell growth on the Lyso-EFMs, mouse fibroblast cells (L929) were utilized. EFMs (0.8 cm × 0.8 cm) were sterilized using UV light overnight before adding the EFMs to a 48-well plate followed by adding L929 cells in a seeding density of 1 × 10 5 cells per well in 1 mL of culture medium. After incubation of the cells together with the EFMs for 48 h at 37°C and 5% CO 2 , the EFMs were washed three times with PBS, and then fixed with 4 v/v% paraformaldehyde in PBS for 20 min.
For observing the morphology of cells growing on EFMs, the samples were dried after the fixing step followed by gold coating and visualization using SEM. For monitoring cell growth, DAPI was used for staining the cell nuclear. After the fixing step, 0.1% Triton-X 100 in PBS was added for 5 min at RT for cell permeabilization, and then 1% fetal bovine serum (FBS) was used for 20 min to reduce nonspecific background staining. Subsequently, the cells were stained with DAPI (10 µg/ mL in PBS) for 5 min. Before each step and after the staining, the cells were washed gently three times with PBS. The stained samples were observed using fluorescence microscope (CellSens, Olympus America Inc., Center Valley, PA, USA).
Statistical analysis
All the data are presented as mean ± standard deviation (SD). Where appropriate, statistical differences are evaluated with t-test using Origin software (v9.1, academic, OriginLab, Northampton, MA, USA). P-values below 5% (p < 0.05) are considered statistically significant.
Results and discussion
Morphology of electrosprayed Lyso-NPs and EFMs
Spherical Lyso-NPs were obtained using electrospray (Fig. 1) , and it was found that the particle appearance was influenced by the solvent selection (binary mixtures of EtOH-H 2 O). The most homogenous particles (approximately 100 nm) were electrosprayed from a lysozyme solution using EtOH-H 2 O (20:80, v/v) as the solvent (Fig. 1A) . With an increase in EtOH amount in the binary solvent mixture, the particles appeared enlarged and poly-dispersed- (Fig. 1B, 1C and 1D ). This size difference might be due to the difference in conductivity of EtOH and H 2 O. Fewer charges accumulated on the particle surface when the amount of EtOH increased in the binary solvent mixture due to its reduced polarity as compared to H 2 O. It is known that high coulomb repulsive force can be generated because of the charges accumulated on the droplet surface [37] . Coulomb repulsion force drives the droplets to break into smaller droplets and thereby, resulting in reduced particle size [38] . Therefore, with an increase in EtOH in the binary solvent, less Coulomb repulsion was generated; hence, part of the droplets could not break up into smaller droplets before reaching the grounded collector. Furthermore, the drying of the droplets became faster with an increase in the proportion of ethanol in the binary solvent mixture. As a result, these droplets were solidified quicker than that containing more water, which prevented them to break up into smaller droplets.
Uniform fibrous mats were obtained for all the EFMs prepared using electrospinning in this study (Supplementary Fig. S1 ). There was no obvious difference between the EFMs with/without the modification of lysozyme and/or PEG. With an increase in the amount of Lyso-NPs in PLGA suspension (> 5:100, Lyso:PLGA, w/w), unstable cone-jet started to present in the electrospinning process. Therefore, lysozyme with mass ratio 2.5:100 (Lyso:PLGA) was selected for the following studies.
Biological activity of lysozyme after electrospray and electrospinning
The bioactivity of lysozyme was investigated for the electrosprayed Lyso-NPs. It was found that the bioactivity is reduced with an increase in EtOH in the binary solvent when comparing to lysozyme raw material ( Fig. 2A) . It might be due to that lysozyme began to aggregate with an increase in EtOH in the binary solvent and thereby, the bioactivity was reduced [39, 40] . However, the bioactivity of the LysoNPs prepared from EtOH-H 2 O (20:80, v/v) decreased more compared to the samples prepared from EtOH-H 2 O 30:70 and 40:60 (v/v). It has been reported that the charges accumulated on the surface of droplets in the electrospray process could alter protein structure conformation [17] . Corresponding to the SEM results, using EtOH-H 2 O (20:80, v/v) as the solvent, the obtained Lyso-NPs had the largest surface area compared to other samples. In addition, due to the higher conductivity of H 2 O compared to EtOH, more charges could be generated on the surface of droplets when using EtOH-H 2 O (20:80, v/v) as the solvent. Therefore, there is a high risk of structure deformation of the lysozyme in the Lyso-NPs prepared from EtOH-H 2 O (20:80, v/v). In this study, the bioactivity of Lyso-NPs prepared from EtOH-H 2 O (30:70, v/v) solution was 100.5 ± 6.9% compared to the untreated lysozyme raw material, which was selected for the following electrospinning studies.
It has previously been reported that using organic solvents to extract protein from hydrophobic polymer carriers to evaluate their bioactivity had a disadvantage of severely destroying protein bioactivity [29, 41] . In order to study the bioactivity of Lyso-NPs after being electrospun, Lyso-NPs were electrosprayed again under the same conditions as A: Bioactivity of Lyso-NPs from the binary solvent EtOH-H 2 O at varied volume ratios. "Lyso" refers to lysozyme raw material; "20EtOH" refers to Lyso-NPs prepared from EtOH-H 2 O (20:80, EtOH:H 2 O, v/v); B: Bioactivity of Lyso-NPs and electrosprayed-(Lyso-NPs). "Lyso-NPs" refers to lysozyme nanoparticels, "ES-(LysoNPs)" and "ES-(Lyso-NPs-PEG)" refer to electrosprayed-(Lyso-NPs) with and without the modification of PEG (Lysozyme: PEG, 1:1, w/w), respectively.
The data represent mean ± SD, n = 3, the * indicate significant difference for p < 0.05. preparing EFMs excluding PLGA. As shown in Fig. 2B , the bioactivity of Lyso-NPs was retained well after being further electrosprayed (mimicking the electrospinning process). There was no statistical difference in bioactivity (p-value of 0.7, 0.1 and 0.4, respectively) for Lyso-NPs and the further electrosprayed-(Lyso-NPs) (ES-(Lyso-NPs)) with and without addition of PEG compared to untreated lysozyme raw material. It suggested that electrospray/electrospinning techniques could be used to incorporate biomacromolecules like lysozyme into hydrophobic polymer carriers without compromising the bioactivity.
Water contact angle of the EFMs
Hydrophilicity is an important quality attribute for wound dressings as it influences cell viability and proliferation rate [42] . The images of WCA of all EFMs are showed in Fig. 3 . It can be observed that the WCA decreased with an increase in the amount of lysozyme in the fibers, which indicated an improved hydrophilicity of EFMs. WCA was found to be 126 ± 2°with 1Lyso (1:100, Lyso:PLGA, w/w), whereas the addition of 2.5Lyso or 5Lyso(2.5:100 or 5:100, Lyso: PLGA, w/w) resulted in WCA of 124 ± 5°and 121 ± 3°, respectively. WCA decreased over time due to water diffusion and penetration into the EFMs. The addition of 10PEG (10:100, PEG:PLGA, w/w) to the EFMs decreased the WCA dramatically from 124 ± 5°(2.5Lyso-EFM) to 42 ± 2°, whereas the addition of 20 PEG (20:100, PEG:PLGA, w/w) made the EFMs so hydrophilic that the WCA was too low to be detected.
Mechanical properties of EFMs
The mechanical properties of EFMs are important as they are expected to provide physical support for wound healing, and the stressstrain curves of EFMs with and without PEG can describe the mechanical properties of the produced fibers (Fig. 4) . The tensile strength and elongation rate at break decreased after adding Lyso-NPs into the EFMs (Fig. 4A) . With PEG modification up to the ration of 5:100 (PEG:PLGA, w/w), the tensile strength and elongation rate at break were almost unchanged. With PEG modification that more than 10:100 (PEG:PLGA, w/w), the tensile strength of EFMs decreased dramatically, however, the elongation rate at break increased (Fig. 4B) . The similar tendency was observed for Young's modulus of all the EFMs (Fig. 5) . It was found that the Young's modulus decreased with an increase in the amount of Lyso-NPs in the EFMs. However, the Young's modulus was nearly unchanged with the addition of PEG up to 5:100 (PEG:PLGA, w/ w) of mass ratio, and decreased dramatically with the addition of PEG to more than 10:100 (PEG:PLGA, w/w). This can possibly be explained by crosslinking of the polymer molecules (PEG and PLGA) being disturbed when suspending the Lyso-NPs in the PLGA solution. This tendency has previously been observed in a similar study of adding PEG into poly-lactic acid (PLA) /poly(butylene succinate) blends [43] . As reported in literature, both tensile strength and Young's modulus will decrease with an increase in PEG. This is due to the fact that PEG can act as a plasticizer in EFMs, however, the elongation rate at break could increase.
It was reported that the Young's modulus and tensile strength of human skin are around 60-70 MPa and 17-21 MPa, respectively [44, 45] . In this study, most of the EMFs had a higher Youngs's modulus and comparable tensile strength, compared to human skin, except for the ones with the PEG modification more than 10:100 (PEG:PLGA, w/ w). Nevertheless, during the wound healing process, the initial epithelialization at the injured site, which performed as a temporary protection layer is only 15% tensile strength of the original skin [46] . Therefore, these EFMs might be able to protect the injured site.
In vitro lysozyme release from the EFMs
The release of lysozyme from EFMs with PLGA was found to be limited as only 5-25% lysozyme was detected in the medium after 56 days (Fig. 6 ). An initial drug loading dependent burst release can be observed for all the samples within the first 4 h. It might be attributed to the fact that more lysozyme accumulate on the surface of fibers during the electrospinning process contributing to the fast release. After the burst release, a plateau is present with very slow lysozyme release until the end of the release study. The plateau might be explained by the fact that the fibrous mats cannot keep their porous structure and began to merge within three weeks in TPBS at 37°C (Fig. 7) . This phenomenon will hinder the release of lysozyme from fibrous mats. After approximately 49 days, the fibrous mats began to disintegrate, resulting in a slightly increase of released lysozyme at the last time points (Fig. 6A) . When comparing the release studies at different temperatures, it can be observed that more lysozyme (were) released at RT than at 37°C (Fig. 6B) . As shown in the SEM images (Fig. 7) , the fibrous mats can keep their integrity after releasing for 56 days with no merging phenomenon appeared at RT. The onset of glass transition of PLGA is around 46°C (Supplementary, Fig. S2 ), close to 37°C, and therefore the polymer molecules became flexible and soft and cannot keep its rigid structure at 37°C. This can explain the faster degradation at 37°C.
The slow and uncompleted drug release behavior is not ideal for successful application in wound healing, and therefore, PEG was added to modify the lysozyme release behaviors. For the EFMs with PEG modification of 10:100 (PEG:PLGA, w/w), the released lysozyme was found to significantly increase from 12.0 ± 3.1% to16.3 ± 1.0% at 37°C (p-value of 0.04), and at RT the release of lysozyme was found to be 24.3 ± 1.9% (Fig. 6B ). However, with PEG modification of 20:100 (PEG:PLGA, w/w), the cumulative release of lysozyme was only 13.2 ± 2.3% at RT. This can be explained by the change of the thermodynamic properties in the physical mixture of PLGA and PEG [47, 48] . In literature, it has been reported that adding PEG to PLA resulted in a decrease in T g due to the improved flexibility [47, 49, 50] . In this study, with an increase in PEG amount, the structure of EFM was easier to merge due to higher molecular mobility and thus, retarding the release of lysozyme.
To further investigate the uncompleted drug release, the samples were collected and analyzed after 56 days of the release study at RT. For the unreleased lysozyme, only further 13-21% was able to dissolve in the release medium, hence, most of the unreleased lysozyme were insoluble aggregates with approximately 46-70% being physical aggregates (urea soluble) and 0.6-2% being disulfidebonded aggregates (dissolved in urea + dithiothreitol) ( Table 1 ). The total recovery of lysozyme was in the range of 84-110% in relation to the total amount of lysozyme loaded into EFMs. Therefore, it was found that most lysozyme was not stable and aggregated during the release study explaining the poor release of lysozyme.
Cytotoxicity of the EFMs
The cytotoxicity of lysozyme loaded EFMs was evaluated using a MTT assay. The samples showed negligible cytotoxicity compared to the control group (cell growing in medium) (Fig. 8) . Both PLGA and PEG are well recognized as safe materials, and are approved by FDA [51, 52] hence, cytotoxicity was not expected. No significant difference of the cell viability was observed for the EFMs compared to the raw material of PLGA. Therefore, the lysozyme loaded fibrous mats prepared in this study was recognized as safe for usage in the future for wound healing.
Cell growth on EFMs
The morphology of L929 fibroblast cells growing on the Lyso-PEG/ PLGA fibrous mats is presented in Fig. 9 . It can be observed that the cells growing on pure PLGA EFMs were stretched and attached along the fibers, whereas the EFMs loaded with lysozyme resulted in round shaped cells and in addition they were also stretched across the interconnected fibrous structure. The cells grew on the superficial layer of 1Lyso-EFMs, and began to penetrate into the fibrous mats with an increase in lysozyme loading (under fibers). The addition of PEG to the EFMs resulted in round shaped cells and they also began to penetrate into the fibrous mats with an increase in PEG amount. The size of L929 Fig. 6 . Lysozyme release from the EFMs in PBS at pH 7.4. A: at 37°C; B: at RT. The data represents mean ± SD, n = 3. Fig. 7 . SEM images of EFMs after the release study at 37°C for 21 days and at RT for 56 days. A: 2.5Lyso-1PEG EFMs and B: 2.5Lyso-5PEG EFMs at 37°C; C: 2.5Lyso-1PEG EFMs and D: 2.5Lyso 5PEG EFMs at RT. cells used in this study was approximately 10 µm, and it can be observed from the SEM images (Fig. 9 ) that the pore size was much smaller than the cells. The reason why the cells can penetrate into the deep layers of the EFMs with much smaller pore size has been interpreted previously [53] . This cell penetration behavior was explained by the ability of the cells to push aside individual fibers in EFMs. If the cells can only grow on the superficial layer and form a tight layer, it will hinder the exchange of oxygen and nutrient and thus hinder wound healing process [42] .
The status of cells growing on the EFMs was observed using DAPI for staining the cell nuclei (Fig. 10) . Apoptotic cells were determined by the signs of change of nucleus from round and homogenous chromatin to polygonal, detached or sparse, shrinkage, condensed chromatin [54, 55] . As observed the cells growing on pure PLGA EFMs were dead with a sign of polygonal shape (Fig. 10) , which might be due to the fact that the PLGA EFMs were too hydrophobic for cells to attach. With an increase in loaded lysozyme, the cells were less polygonal in shape, and by the addition of PEG, the nuclei showed round and homogenous chromatin indicating good cell growth status, especially 2.5Lyso-5PEG-EFMs and 2.5Lyso -10PEG-EFMs. Both lysozyme and PEG can improve the hydrophilicity of EFMs, consequently, improving the affinity between cells and EFMs and facilitating cell attachment and growing.
Conclusion
Lysozyme nanoparticles loaded PLGA EFMs were prepared using electrospray/electrospinning. Negligible influence on the bioactivity of lysozyme was observed while being processed using 'protein friendly' solvents, i.e. binary solvent of EtOH-H 2 O in this study. Electrospinning is demonstrated to be a competitive technique to fabricate biomacromolecules loaded fibrous mats with well-retained bioactivity. With an addition of PEG, the hydrophilicity of PLGA EFMs could be improved, which facilitated the proliferation of fibroblast cells (L929) on EFMs. The ability of cell compatibility and proliferation made the EFMs a potential candidate in the future for wound healing. 
